Sign in
Not yet recruitingPhase 1/2

Udonitrectag added to usual care for diabetic foot ulcers

Tests udonitrectag plus usual care in adults with diabetic foot ulcers.

Key facts

Who runs it
Mimetech S.r.l.
Where
Italy5 sites in 1 countryChoose a country to see its sites
Registry title
NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
24 people, planned
Started
1 Jul 2021
Planned end
31 Mar 2025
Type of study
Interventional
Record updated
25 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 or 2 diabetes who have a foot ulcer that is not healing. It tests udonitrectag (MT8) added to standard care, compared with standard care alone.

Age
18 years or older
Sex
Men and women
Disease stage
Diabetic foot wound grade I or II on the TEXAS scale, with infection grade 1 on the PEDIS scale. Ulcer area from 2 to 15 cm2. TpO2 >= 30 mmHg or ABI >= 0.70.
Earlier treatment
The ulcer has not healed with standard good care in the last 2-weeks (area shrank less than 20%). No other investigational product within 30 days before study treatment.
Biomarker or test result
HbA1c <=10% (or <= 86 mmol/mol). Women who can have children need a negative urine pregnancy test.

Main reasons for not taking part

  • Pregnant or breast-feeding women
  • Autoimmune disease, weak immune system, or high-dose steroids or immunosuppressants
  • Current smokers
  • Severe kidney failure (eGFR< 30 ml/min), current cancer, or severe heart or liver disease
  • Infected ulcer above grade 1, ulcer from other causes, or surgery or amputation planned during the study

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Females of childbearing potential must have a negative urine pregnancy test prior to commencing the study
  • Glycated haemoglobin (HbA1c) levels <=10% (or <= 86 mmol/mol)
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
  • For males with partners reproductive potential: use of condoms or other methods to ensure effective contraception with partner
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female
  • Age >=18 years
  • Diagnosis of type 1 or 2 diabetes mellitus
  • A diabetic foot wound grade I or II, according to the TEXAS diabetic wound classification system and grading 1 in the PEDIS infection scale
  • TpO2>= 30 mmHg or ABI (Ankle Brachial Index) >= 0.70
  • Ulcers not healing with standard good care in the last 2-weeks (ulcer area reduction less than 20% versus baseline)
  • Presence of ulcer with an area from 2 to 15 cm2 measured by MolecuLight i:XTM Wound Imaging Device

Who cannot take part

  • History of any medical or psychiatric conditions that, according to the Investigator, may increase the risks associated with the study’s participation or investigational product(s) administration
  • Current use of high-dose steroids or immunosuppressants
  • Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to study treatment (Visit 1a o Visit 1b)
  • Diagnosis of severe medical conditions such as severe heart failure or severe hepatic disease, according to the Investigator’s judgment or presence of concurrent illness indicating a short life expectancy
  • Diagnosis of current of autoimmune disorders
  • Patients with ulcers due to other etiologies (e.g., arterial insufficiency)
  • Febrile illness within one month from Visit 1b
  • Blood pressure above 180/100 or heart rate>100 bpm or Respiratory frequency >30
  • Patients who show reductions or enlargement of the ulcer area >20% during the screening phase will not be enrolled for the study
  • Presence of infected foot ulcer of grade >1 (according to the PEDIS diabetic foot ulcer classification system), diagnosed via a clinic examination
  • Clinical diagnosis of peripheral vascular disease (PVD) requiring a prompt revascularization
  • Any surgery planned in the study period, including scheduled amputation at the ulcer site
  • Diagnosis of current cancer
  • Patients with diabetes under poor control (HbA1c of >10% or >86 mmol/mol)
  • Severe renal failure defined as eGFR< 30 ml/min
  • Pregnancy or Lactation. Female patients who are pregnant or breast-feeding
  • Immunosuppressed subjects
  • Current smoker
  • Childbearing potential female patients who do not agree to use an acceptable method of contraception during the study, providing they are not pregnant or lactating

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the safety, tolerability, and pharmacokinetic profile of udonitrectag (MT8) added to standard of care versus standard of care alone in the treatment of Diabetic Foot Ulcers.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS
Plain-language title
Udonitrectag added to usual care for diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
25 September 2025